Jaka jest cena za Catalent, Inc. (CTLT)

Cena za Catalent, Inc. (CTLT) wynosi $63.48

Jaka jest kapitalizacja rynkowa dla Catalent, Inc. (CTLT)

Kapitalizacja rynkowa dla Catalent, Inc. (CTLT) wynosi $11.52B

Przychody Catalent, Inc. (CTLT)

Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.

Rok	Przychody	Zmień
2026 (TTM)	$4.42B	0.94%
2024	$4.38B	2.46%
2023	$4.28B	-11.43%
2022	$4.83B	20.76%
2021	$4.00B	29.21%
2020	$3.09B	22.89%
2019	$2.52B	2.22%
2018	$2.46B	18.70%
2017	$2.08B	12.30%
2016	$1.85B	0.94%
2015	$1.83B	0.17%
2014	$1.83B	1.52%
2013	$1.80B	6.22%
2012	$1.69B	10.64%
2011	$1.53B	0.00%

Rok

Przychody

Zmień

2026 (TTM)

$4.42B

0.94%

2024

$4.38B

2.46%

2023

$4.28B

-11.43%

2022

$4.83B

20.76%

2021

$4.00B

29.21%

2020

$3.09B

22.89%

2019

$2.52B

2.22%

2018

$2.46B

18.70%

2017

$2.08B

12.30%

2016

$1.85B

0.94%

2015

$1.83B

0.17%

2014

$1.83B

1.52%

2013

$1.80B

6.22%

2012

$1.69B

10.64%

2011

$1.53B

0.00%

Firma	Przychody	Różnica w przychodach	Kraj
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	49.52%	IN

Firma

Przychody

Różnica w przychodach

Kraj